Merck & Co., Inc. (MRK) is set to announce its fiscal fourth-quarter earnings for 2025 on Feb. 3. Analysts predict a profit of $2.08 per share, up 20.9% from the previous year. For the full year, MRK is expected to report EPS of $8.99, up 17.5% from fiscal 2024.

Despite underperforming the S&P 500 and Health Care Select Sector, MRK faces challenges like regulatory scrutiny, pricing pressures, and generic competition. Slow Keytruda growth and declining sales in China are also impacting the company. On Oct. 30, 2025, MRK reported Q3 results that beat Wall Street expectations.

Analysts have a moderately bullish outlook on MRK stock, with a consensus rating of “Moderate Buy.” The average analyst price target is $111.35, indicating a potential upside of 3.6% from current levels. All information in this article is for informational purposes only and was originally published on Barchart.com.

Read more at Yahoo Finance: Merck & Co.’s Q4 2025 Earnings: What to Expect